Capricor Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hello, everyone. I'm Kristen Kluska, one of the biotechnology analysts at Cantor. It's my pleasure to host Capricor Therapeutics today. Joining me on our fireside chat is Dr. Linda Marban, the President, CEO, Director; and AJ Bergmann, the CFO. Thank you for joining us and for being at our conference.
We're delighted. Thank you, Kristin.
Questions & Answers
Great. So let's start with some questions about the platform and the technologies, specifically related to your cell therapy program. I think this is a space where companies have traditionally all been viewed under the same umbrella around stem and cell therapies. So, could you please walk through the differentiated profile of CAP-1002, which consists of allogeneic cardiosphere-derived cells that work to secrete exosomes?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |